Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;281(5):2619-2626.
doi: 10.1007/s00405-024-08528-w. Epub 2024 Mar 1.

Head and neck cancer patients with geriatric deficits are more often non-responders and lost from follow-up in quality of life studies

Julius de Vries  1 , Dannie J Vermue  1 , Grigory Sidorenkov  2 , Suzanne Festen  3 , Johannes A Langendijk  4 , Geertruida H de Bock  2 , Gyorgy B Halmos  5
Affiliations

Head and neck cancer patients with geriatric deficits are more often non-responders and lost from follow-up in quality of life studies

Julius de Vries et al. Eur Arch Otorhinolaryngol. 2024 May.

Abstract

Objectives: To identify associations between frailty and non-response to follow-up questionnaires, in a longitudinal head and neck cancer (HNC) study with patient-reported outcome measures (PROMs).

Materials and methods: Patients referred with HNC were included in OncoLifeS, a prospective data-biobank, underwent Geriatric Assessment (GA) and frailty screening ahead of treatment, and were followed up at 3, 6, 12 and 24 months after treatment using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Head and Neck 35. Statistical analysis for factors associated with non-response was done using Generalized Linear Mixed Models.

Results: 289 patients were eligible for analysis. Mean age was 68.4 years and 68.5% were male. Restrictions in Activities of Daily Living [OR 4.46 (2.04-9.78)] and Instrumental Activities of Daily Living [OR 4.33 (2.27-8.24)], impaired mobility on Timed Up and Go test [OR 3.95 (1.85-8.45)], cognitive decline [OR 4.85 (2.28-10.35)] and assisted living (OR 5.54 (2.63-11.67)] were significantly associated with non-response. Frailty screening, with Geriatric 8 and Groningen Frailty Indicator, was also associated with non-response [OR, respectively, 2.64 (1.51-4.59) and 2.52 (1.44-4.44)]. All findings remained significant when adjusted for other factors that were significantly associated with non-response, such as higher age, longer study duration and subsequent death.

Conclusion: Frail HNC patients respond significantly worse to follow-up PROMs. The drop-out and underrepresentation of frail patients in studies may lead to attrition bias, and as a result underestimating the effect sizes of associations. This is of importance when handling and interpreting such data.

Keywords: Bias; Geriatric deficit; Head and neck cancer; Lost from follow-up; Non-response to questionnaires; Patient-reported outcome measures.

PubMed Disclaimer

Conflict of interest statement

JAL declared receiving Grants from the European Union and Dutch Cancer Society, receiving consulting fees and honorarium from IBA, paid to UMCG Research BV, receiving research grants from IBA, RaySearch, Elekta, Mirada and Siemens, serving in the monitoring or advisory board of UMCN, IBA and RaySearch, and serving as chair of the NVRO. The other authors reported no disclosures.

Figures

Fig. 1
Fig. 1
Flowchart of study inclusion. * = experimental or unknown treatment. n = number
Fig. 2
Fig. 2
Response and non-response to questionnaires, recurrence and death among patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pilleron S, Sarfati D, Janssen-Heijnen M, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144(1):49–58. doi: 10.1002/ijc.31664. - DOI - PubMed
    1. Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100(Suppl 1):S105–S112. doi: 10.2105/AJPH.2009.162982. - DOI - PMC - PubMed
    1. Singh H, Kanapuru B, Smith C, et al. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration. J Clin Oncol. 2017;35(15_suppl):10009. doi: 10.1200/JCO.2017.35.15_suppl.10009. - DOI
    1. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30(17):2036–2038. doi: 10.1200/JCO.2012.41.6727. - DOI - PubMed
    1. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383–1389. doi: 10.1200/JCO.2003.08.010. - DOI - PubMed